Nareg Sagherian | executive |
David Moatazedi | executive |
Sandra Beaver | executive |
Annabel Samimy | analyst |
Marc Goodman | analyst |
Navann Ty Dietschi | analyst |
Uy Ear | analyst |
Douglas Tsao | analyst |
Serge Belanger | analyst |
Mikaela Franceschina | analyst |
Please go ahead.
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' first quarter 2024 financial results.
Our first quarter 2021 press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; and Sandra Beaver, Chief Financial Officer; [ Louis Avelar ], Chief Medical Officer and Head of R&D, is also with us for the Q&A portion of the call.
Before we begin our discussion, I'd like to note that during our call, our prepared remarks will include forward-looking statements within the meaning of United States securities laws, and management may make additional forward-looking statements in response to your questions.
Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the company's business, strategy, operations or financial performance.